» Articles » PMID: 34321889

ILT4 in Colorectal Cancer Cells Induces Suppressive T Cell Contexture and Disease Progression

Overview
Publisher Dove Medical Press
Specialty Oncology
Date 2021 Jul 29
PMID 34321889
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Immune checkpoint blockade (ICB) therapy shows little or no clinical benefit in most colorectal cancer (CRC) patients, due to the immunosuppressive T cell contexture in the tumor microenvironment (TME). Immunoglobulin-like transcript (ILT) 4 is an immunosuppressive molecule in myeloid cells. ILT4 is enriched in solid tumor cells, facilitating their proliferation, invasion, and metastasis. However, the regulatory role of ILT4 in T cell immunity of CRC is still undetermined. Here, we aimed to explore how tumor cell-derived ILT4 orchestrates T cell infiltration, subset distribution, and function in CRC.

Methods: A total of 145 paraffin-embedded cancer tissues and the corresponding clinicopathological information were collected from CRC patients. Immunohistochemical (IHC) staining and public database analyses determined the correlation of ILT4 expression with different T cell subset densities, IFN-γ levels, and patient outcomes. Paired Ig-like receptor B (PIR-B, ILT4 mouse ortholog)-overexpressing/-downregulated MC38 cells were subcutaneously injected into C57BL/6 mice as a CRC transplantation model. The frequencies, subsets, and IFN-γ levels of T cells in mouse blood and spleens were determined using flow cytometry and immunohistochemistry, respectively.

Results: High ILT4 expression in CRC cells was associated with decreased T cell infiltration, disease progression, and poor patient survival. T cell subset analyses indicated that ILT4-high patients showed reduced CD8 T cell but elevated FOXP3 regulatory T (Treg) cell frequencies in the TME. High ILT4 levels predicted lower IFN-γ production by tumor-infiltrating lymphocytes (TILs), especially by CD8T cells in human CRC tissues. Moreover, PIR-B overexpression accelerated MC38 growth in mice, decreased CD3/CD8/IFN-γ T cell densities, and elevated Treg infiltration in the TME, blood, and spleens. PIR-B knockdown had the opposite effects.

Conclusion: ILT4 in CRC cells induced immunosuppressive T cell subset infiltration and impaired IFN-γ production in TILs, suggesting that ILT4 might be a potential immunotherapeutic target and prognostic biomarker.

Citing Articles

Targeting leukocyte immunoglobulin‑like receptor B2 in the tumor microenvironment: A new treatment prospect for solid tumors (Review).

Cao M, Luan J, Zhai C, Liu H, Zhang Z, Guo N Oncol Lett. 2025; 29(4):181.

PMID: 39990807 PMC: 11843431. DOI: 10.3892/ol.2025.14927.


LILRB2 promotes immune escape in breast cancer cells via enhanced HLA-A degradation.

Jiang Z, Huang Q, Chang Y, Qiu Y, Cheng H, Yang M Cell Oncol (Dordr). 2024; 47(5):1679-1696.

PMID: 38656573 DOI: 10.1007/s13402-024-00947-5.


ILT4 facilitates angiogenesis in non-small cell lung cancer.

Wang S, Wang J, Gong W, Zhang F, Chen X, Xu H Cancer Sci. 2024; 115(5):1459-1475.

PMID: 38433526 PMC: 11093198. DOI: 10.1111/cas.16126.


Analysis of HLA-G 14 bp Insertion/Deletion Polymorphism and HLA-G, ILT2 and ILT4 Expression in Head and Neck Squamous Cell Carcinoma Patients.

Durmanova V, Tedla M, Rada D, Bandzuchova H, Kuba D, Suchankova M Diseases. 2024; 12(2).

PMID: 38391781 PMC: 10888050. DOI: 10.3390/diseases12020034.


Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer.

Wang M, Zhu L, Yang X, Li J, Liu Y, Tang Y Front Pharmacol. 2023; 14:1132158.

PMID: 36874015 PMC: 9974851. DOI: 10.3389/fphar.2023.1132158.


References
1.
Liu X, Yu X, Xie J, Zhan M, Yu Z, Xie L . ANGPTL2/LILRB2 signaling promotes the propagation of lung cancer cells. Oncotarget. 2015; 6(25):21004-15. PMC: 4673246. DOI: 10.18632/oncotarget.4217. View

2.
Le D, Uram J, Wang H, Bartlett B, Kemberling H, Eyring A . PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015; 372(26):2509-20. PMC: 4481136. DOI: 10.1056/NEJMoa1500596. View

3.
Dunn G, Koebel C, Schreiber R . Interferons, immunity and cancer immunoediting. Nat Rev Immunol. 2006; 6(11):836-48. DOI: 10.1038/nri1961. View

4.
Ciardiello D, Vitiello P, Cardone C, Martini G, Troiani T, Martinelli E . Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy. Cancer Treat Rev. 2019; 76:22-32. DOI: 10.1016/j.ctrv.2019.04.003. View

5.
Guo L, Wang C, Qiu X, Pu X, Chang P . Colorectal Cancer Immune Infiltrates: Significance in Patient Prognosis and Immunotherapeutic Efficacy. Front Immunol. 2020; 11:1052. PMC: 7270196. DOI: 10.3389/fimmu.2020.01052. View